Drug Discovery World

FEBRUARY 28, 2024

Using a technique they’ve dubbed ‘cancer shredding’, the researchers at Gladstone Institutes, California, programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at them.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

OCTOBER 16, 2023

CellProthera selected the UK centres for their excellence in the conduct of clinical research with dedicated staff, equipment, availability of imaging platforms and high interest in cell therapy cardiovascular trials especially University Hospital of Birmingham equipped with a bi-plane Cathlab.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

JUNE 5, 2023

The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL. How can a biotech begin to shape and mould its culture, into something new and established? We started about three years ago and since then, we’ve been on a growing journey of fundraising and expanding the team.

Genome 52

Genome Genomics Life Science Genetics 52

The Pharma Data

APRIL 11, 2023

The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development.

Research 40

Research Clinical Trials Clinical Trials Trials 40

Delveinsight

JULY 29, 2020

Zydus has started the human clinical trials of its plasmid DNA based vaccine, ZyCoV-D. USA to develop Covid-19 vaccine, through a Joint Venture company to be based in Ireland. Similar is the case in Indian pharmaceutical industry. Zydus is working on Covid-19 vaccine ZyCoV-D.

Vaccination 62

Vaccination Vaccine Clinical Trials Clinical Trials 62

XTalks

JANUARY 19, 2024

When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death. For example, non-target effects such as the release of damaged DNA into the cytoplasm of irradiated cells can lead to the activation of immune cells.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

APRIL 29, 2024

Scott Kobayashi, Senior Vice President of Sales, BioPhy: Kobayashi previously founded Delta Project Management, a life sciences consulting firm he sold to Versita in 2022, and held consulting roles with companies like Pfizer, Genentech, and Flour.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($19.19 billion USD), a 13.30

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

MARCH 6, 2024

They also involve multiple mutations in non-coding regions of DNA – the ‘dark genome’ which makes up around 98% of our DNA. An example of this is our clinical development partnerships with clinical-stage pharmaceutical companies like Nanopharmaceutics.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

XTalks

OCTOBER 26, 2023

Kierstead joined PPD in 2009 and is currently an executive director of the vaccine sciences lab. She has 23 years of experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission. It worked in the favor of vaccine makers that X.BB.1.5

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

NOVEMBER 30, 2023

Lonza’s integrated CMC strategy and timeline was presented, as well as case studies highlighting key approaches and technologies, including: vector design & integration, cell line selection, downstream process, analytical method and formulation development. kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . Hamish Ryder.

HR 52

HR Research Drugs Development 52

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Drug Discovery World

NOVEMBER 13, 2023

The track will be opened by chairperson remarks from Daniel Chen, MD, PhD, Founder, Engenuity Life Sciences, which will be followed by the track’s keynote presentation by Bent Jakobsen, PhD, FMedSci, CEO & Founder, Accession Therapeutics. It is called, ‘An unexpected future for immune oncology therapies?’

Protein 59

Protein Antibody Engineer Scientist 59

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

XTalks

FEBRUARY 3, 2021

Johnson & Johnson’s single-shot DNA vaccine candidate was shown to have an overall effectiveness of 66 percent in preventing moderate to severe COVID-19. Johnson & Johnson’s DNA Vaccine. The DNA vaccine was created using Janssen’s AdVac technology platform that is designed for rapid vaccine development.

Vaccination 103

Vaccination Vaccine Trials Protein 103

XTalks

SEPTEMBER 14, 2020

Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like. Addressing the Rapidly Evolving Vaccine Development Landscape.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92